{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:49:50Z","timestamp":1791902990907,"version":"4.3.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2002,7,1]],"date-time":"2002-07-01T00:00:00Z","timestamp":1025481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chest"],"published-print":{"date-parts":[[2002,7]]},"DOI":"10.1378\/chest.122.1.227","type":"journal-article","created":{"date-parts":[[2003,6,14]],"date-time":"2003-06-14T00:09:19Z","timestamp":1055549359000},"page":"227-232","source":"Crossref","is-referenced-by-count":151,"title":["Thalidomide for Chronic Sarcoidosis"],"prefix":"10.1016","volume":"122","author":[{"given":"Robert P.","family":"Baughman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Judson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin S.","family":"Teirstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Moller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyse E.","family":"Lower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1378\/chest.122.1.227_bib1","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/cpt196563303","article-title":"Thalidomide in the treatment of lepra reaction","volume":"6","author":"Sheskin","year":"1965","journal-title":"Clin Pharmacol Ther"},{"key":"10.1378\/chest.122.1.227_bib2","first-page":"291","article-title":"Thalidomide responsive chronic pulmonary GVHD","volume":"17","author":"Forsyth","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.1378\/chest.122.1.227_bib3","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1089\/aid.1997.13.1625","article-title":"A double-blind placebo-controlled phase II trial of thalidomide in asymptomatic HIV-positive patients: clinical tolerance and effect on activation markers and cytokines","volume":"13","author":"Marriott","year":"1997","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1378\/chest.122.1.227_bib4","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0003-4975(94)00870-D","article-title":"Thalidomide as replacement for steroids in immunosuppression after lung transplantation","volume":"59","author":"Uthoff","year":"1995","journal-title":"Ann Thorac Surg"},{"key":"10.1378\/chest.122.1.227_bib5","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.122.1.227_bib6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0962-8479(97)90015-0","article-title":"Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis","volume":"78","author":"Moreira","year":"1997","journal-title":"Tuber Lung Dis"},{"key":"10.1378\/chest.122.1.227_bib7","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/BF03401576","article-title":"Thalidomide treatment reduces tumor necrosis factor \u03b1 production and enhances weight gain in patients with pulmonary tuberculosis","volume":"1","author":"Tramontana","year":"1995","journal-title":"Mol Med"},{"key":"10.1378\/chest.122.1.227_bib8","first-page":"736","article-title":"adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999","volume":"160","author":"Statement on sarcoidosis: Joint Statement of the American Thoracic Society (ATS)","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.122.1.227_bib9","first-page":"747","article-title":"Current concepts of the pathogenesis of sarcoidosis","volume":"135","author":"Thomas","year":"1987","journal-title":"Am Rev Respir Dis"},{"key":"10.1378\/chest.122.1.227_bib10","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1378\/chest.103.3.832","article-title":"The relationship between alveolar macrophage TNF, IL-1, and PGE2 release, alveolitis, and disease severity in sarcoidosis","volume":"103","author":"Pueringer","year":"1993","journal-title":"Chest"},{"key":"10.1378\/chest.122.1.227_bib11","first-page":"36","article-title":"Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis","volume":"115","author":"Baughman","year":"1990","journal-title":"J Lab Clin Med"},{"key":"10.1378\/chest.122.1.227_bib12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0954-6111(97)90134-7","article-title":"Thalidomide reduces tumour necrosis factor-\u03b1 production by human alveolar macrophages","volume":"91","author":"Tavares","year":"1997","journal-title":"Respir Med"},{"key":"10.1378\/chest.122.1.227_bib13","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/0190-9622(95)91549-4","article-title":"Treatment of cutaneous and pulmonary sarcoidosis with thalidomide","volume":"32","author":"Carlesimo","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"10.1378\/chest.122.1.227_bib14","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S0190-9622(98)70360-3","article-title":"Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report","volume":"39","author":"Lee","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1378\/chest.122.1.227_bib15","first-page":"525","article-title":"Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients","volume":"208","author":"Neville","year":"1983","journal-title":"Q J Med"},{"key":"10.1378\/chest.122.1.227_bib16","first-page":"121","article-title":"Alternatives to corticosteroids in the treatment of sarcoidosis","volume":"14","author":"Baughman","year":"1997","journal-title":"Sarcoidosis"},{"key":"10.1378\/chest.122.1.227_bib17","first-page":"75","article-title":"Defining organ involvement in sarcoidosis: the ACCESS proposed instrument","volume":"16","author":"Judson","year":"1999","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1378\/chest.122.1.227_bib18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1164\/ajrccm.159.1.9712108","article-title":"Spirometric reference values from a sample of the general U.S. population","volume":"159","author":"Hankinson","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.122.1.227_bib19","first-page":"635","article-title":"Reliability of a widely used test of peripheral cutaneous vibration sensitivity and a comparison of two testing protocols","volume":"45","author":"Gerr","year":"1988","journal-title":"Br J Ind Med"},{"key":"10.1378\/chest.122.1.227_bib20","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1365-2230.1985.tb00571.x","article-title":"Invasive nasal sarcoidosis treated with methotrexate","volume":"10","author":"Fenton","year":"1985","journal-title":"Clin Exp Dermatol"},{"key":"10.1378\/chest.122.1.227_bib21","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2500\/105065800782102753","article-title":"Nasal and sinus manifestations of sarcoidosis","volume":"14","author":"Zeitlin","year":"2000","journal-title":"Am J Rhinol"},{"key":"10.1378\/chest.122.1.227_bib22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0962-8479(97)90015-0","article-title":"Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis","volume":"78","author":"Moreira","year":"1997","journal-title":"Tuber Lung Dis"},{"key":"10.1378\/chest.122.1.227_bib23","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJM199705223362103","article-title":"Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection: National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group","volume":"336","author":"Jacobson","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.122.1.227_bib24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0162-3109(98)00010-1","article-title":"Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells","volume":"40","author":"Rowland","year":"1998","journal-title":"Immunopharmacology"},{"key":"10.1378\/chest.122.1.227_bib25","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1164\/ajrccm\/142.6_Pt_1.1268","article-title":"The effect of corticosteroid or methotrexate therapy on lung lymphocytes and macrophages in sarcoidosis","volume":"142","author":"Baughman","year":"1990","journal-title":"Am Rev Respir Dis"},{"key":"10.1378\/chest.122.1.227_bib26","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.4049\/jimmunol.156.12.4952","article-title":"Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis","volume":"156","author":"Moller","year":"1996","journal-title":"J Immunol"},{"key":"10.1378\/chest.122.1.227_bib27","doi-asserted-by":"crossref","first-page":"5157","DOI":"10.4049\/jimmunol.159.10.5157","article-title":"Inhibition of IL-12 production by thalidomide","volume":"159","author":"Moller","year":"1997","journal-title":"J Immunol"},{"key":"10.1378\/chest.122.1.227_bib28","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","article-title":"Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-\u03b1","volume":"163","author":"Corral","year":"1999","journal-title":"J Immunol"},{"key":"10.1378\/chest.122.1.227_bib29","doi-asserted-by":"crossref","first-page":"443","DOI":"10.7326\/0003-4819-128-6-199803150-00004","article-title":"Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome","volume":"128","author":"Hamuryudan","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.122.1.227_bib30","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00000441-199003000-00002","article-title":"The use of low dose methotrexate in refractory sarcoidosis","volume":"299","author":"Lower","year":"1990","journal-title":"Am J Med Sci"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001236921646304X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001236921646304X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:02:20Z","timestamp":1704844940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001236921646304X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,7]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,7]]}},"alternative-id":["S001236921646304X"],"URL":"https:\/\/doi.org\/10.1378\/chest.122.1.227","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2002,7]]}}}